POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison

X Leleu,T Delea,P Guyot,A Moynahan, E Singh, C Tekle, P Lin

Value in Health（2022）

Cited 1|Views1

No score

Abstract

ICARIA trial (NCT02990338) evaluated isatuximab (Isa) plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM) after ≥two prior lines of therapy (LOTs). In the absence of head-to-head trials, we compared efficacy and safety of IsaPd versus daratumumab+Pd (DPd) [APOLLO; NCT03180736], using a matching-adjusted indirect comparison (MAIC).

Translated text

Key words

multiple myeloma,isatuximab plus pomalidomide,dexamethasone,matching-adjusted

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined